Biophytis SA and LynxKite Technologies have announced a strategic partnership aimed at enhancing AI-driven drug discovery, specifically focused on next-generation therapies for longevity. This collaboration, unveiled on March 13, 2026, will build upon the existing MASSIVE project (Mas Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy) and expand to include additional modalities.
The initiative is supported by Singapore’s Enterprise Singapore and aligns with the country’s Research, Innovation and Enterprise (RIE) 2030 plan, emphasizing the importance of advanced analytics and artificial intelligence in the life sciences sector.
Under the collaboration, LynxKite will utilize its cutting-edge AI computational methods to develop a computational longevity platform. This platform will feature unique curated datasets and accelerated computation techniques relevant to longevity research. Among the key focuses will be the development of drug candidates targeting sarcopenia, a degenerative muscle disease that affects millions of elderly individuals globally, as well as candidates for dry age-related macular degeneration.
Stanislas Veillet, CEO of Biophytis, stated, “The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite’s innovative AI to accelerate the discovery of transformative therapies against sarcopenia.” Meanwhile, Gyorgy Lajtai, CEO of LynxKite, expressed pride in the collaboration, emphasizing its potential to revolutionize drug discovery through the integration of computational tools across various modalities.
Key Objectives of the Partnership
The partnership’s primary goals include several innovative approaches to drug discovery. These objectives involve modeling the Mas receptor for structure-based drug design, designing and prioritizing synthetic drug candidates through AI-guided molecule generation, and testing promising MasR activators for biological activity and safety. The collaboration aims to synthesize and select lead candidates while also securing patent protections in preparation for preclinical development.
LynxKite brings over a decade of experience in advanced analytics, having collaborated with more than 100 global enterprises, including renowned companies like Roche and AstraZeneca. The company’s flagship platform, known for its open-source capabilities, will support the computational orchestration necessary for the project.
Biophytis, headquartered in Paris, specializes in developing drug candidates for age-related diseases. Its lead candidate, BIO101 (20-hydroxyecdysone), is currently advancing through clinical trials for conditions related to muscular degeneration and metabolic disorders. The company operates subsidiaries in Cambridge, Massachusetts, and Brazil, with shares listed on Euronext Growth Paris.
Technological Advancements and Future Potential
The collaboration with LynxKite will also leverage advanced technologies such as chemoinformatics and software engineering, along with the latest generation of NVIDIA toolkits for GPU computation. This technological integration is expected to enhance the efficiency and effectiveness of the drug discovery process.
Biophytis aims to harness this partnership not only to advance its strategic drug discovery program but also to align with its focus on longevity therapeutics. The incorporation of AI-driven methodologies promises to accelerate the timeline for bringing new therapies to market, addressing significant unmet medical needs in aging populations.
Both companies are poised to lead in the evolving field of computational longevity, setting a foundation for future innovations that could transform the landscape of age-related disease therapies. As they embark on this ambitious project, the partnership reflects a broader trend of leveraging artificial intelligence to solve complex challenges in healthcare.
For more information about LynxKite Technologies, visit their official website at [www.lynxkite.com](https://lynxkite.com), and for Biophytis, check [www.biophytis.com](http://www.biophytis.com).
